tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Reata Pharmaceuticals downgraded to Neutral from Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Charles Duncan downgraded Reata Pharmaceuticals (RETA) to Neutral from Overweight after Biogen (BIIB) agreed to acquire Reata for $172.50 per share in cash.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on RETA:

Disclaimer & DisclosureReport an Issue

1